Tuesday, August 28, 2018 2:16:37 AM
bout how TargeGen was able to discover its lead drug candidate, TG101348, in-house, and was able to bring it into clinical trials in 18 months with the help of a China-based contract research organization, WuXi Pharmatech. Two years later, the company had proven the concept with data from a mid-stage clinical trial that paved the way for today’s acquisition. Now it will be up to Sanofi to see just how lucrative this drug might be for investors, and valuable it may be for patients. Incyte may reach the market first in this category, Royston says, but he says the TargeGen drug could be the ultimate winner.
Recent CLSD News
- Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD • GlobeNewswire Inc. • 08/27/2024 11:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2024 08:30:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 08:15:08 PM
- Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/12/2024 08:05:00 PM
- Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference • GlobeNewswire Inc. • 08/08/2024 11:05:00 AM
- Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024 • GlobeNewswire Inc. • 08/01/2024 11:05:00 AM
- Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of ARCATUS® for Suprachoroidal Use in Uveitic Macular Edema Patients in China • GlobeNewswire Inc. • 07/29/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:55:18 AM
- Clearside Biomedical Opens Registration for Suprachoroidal Delivery KOL Webinar to Be Held on Wednesday, July 24, 2024 at 8:00 am ET • GlobeNewswire Inc. • 07/22/2024 04:00:00 PM
- Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board • GlobeNewswire Inc. • 07/11/2024 11:05:00 AM
- Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery • GlobeNewswire Inc. • 06/27/2024 11:05:00 AM
- Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting • GlobeNewswire Inc. • 06/12/2024 11:05:00 AM
- Clearside Biomedical Announces Publication of Consensus Guidelines for Drug Delivery via Suprachoroidal Space (SCS®) Injection in Leading Peer-Reviewed Industry Journal, RETINA® • GlobeNewswire Inc. • 05/21/2024 11:05:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/10/2024 08:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:10:43 PM
- Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/09/2024 08:05:00 PM
- Clearside Biomedical to Participate in Fireside Chat at the Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/08/2024 08:15:00 PM
- Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 • GlobeNewswire Inc. • 04/30/2024 11:05:00 AM
- Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors • GlobeNewswire Inc. • 04/16/2024 11:05:00 AM
- Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:05:00 AM
- Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 11:05:00 AM
- Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024 • GlobeNewswire Inc. • 02/29/2024 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 10:05:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/08/2024 09:52:44 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM